ArticleCureus2024
Successful Treatment of Adalimumab-Induced Paradoxical Skin Reactions in Pustulotic Arthro-Osteitis With Guselkumab.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SAPHO syndrome and pustular skin diseases: shared inflammatory circuits, divergent tissue outcomes, and the limits of a spectrum model.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pustulotic arthro-osteitis (PAO) is a significant comorbidity of palmoplantar pustulosis (PPP), with biologics targeting tumor necrosis factor (TNF)-α, interleukin (IL)-12/23 p40, IL-23 p19, and IL-17 showing clinical benefits for PPP/PAO. However, patients receiving these biological agents frequently experience paradoxical skin reactions (PSRs), particularly with anti-TNF-α treatments. We report a case of PPP/PAO treated with the anti-TNF-α agent adalimumab, which led to the development of PSRs, including psoriasis-like and folliculitis-like rashes, and acute hair loss. Subsequently, treatment was changed to guselkumab, an anti-IL-23 p19 monoclonal antibody, which successfully controlled both PPP/PAO and PSRs. To date, no PSRs associated with anti-IL-23 agents in PAO have been reported. A study from Japan indicates that guselkumab and adalimumab have similar efficacy in treating PAO. Given that anti-IL-23 agents are approved for refractory PPP under the Japanese health insurance system, we recommend their use over adalimumab in PPP/PAO patients to prevent PSRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.